Age-specific features of acute myeloid leukemia karyotype


Cite item

Full Text

Abstract

Aim. To study distribution of some karyotype variants among patients of different age with acute myeloid leukemia (AML).
Material and methods. Distribution of balanced, normal, unbalanced, complex and monosomic
karyotype among 244 patients with de novo AML in age groups 16-20, 21-30, 31-40, 41-50, 51-60, 61 and older was analysed.
Results. There is difference in frequency of balanced and complex karyotype in patients under and over 60 years. Number of AML patients with balanced aberrations including favourable variants t(8;21), t(15;17) and inv(16) falls after 60 years of age (6.7% versus 15.0% in patients aged 16-20 years; p < 0.001), while a complex karyotype occurs more frequently in AML patients at the age of 61 and older (56.8% versus 2.7% in the group 16-20 years; p < 0.001). With age, more frequently detected is the most unfavourable monosomic karyotype with aberrations similar to those in myelodysplastic syndrome (57.1% in patients aged 16-60 years and in 80.0% in the group of 61 years of age and over).
Conclusion. Age-specific karyotype features detected may be explained by different biological mechanisms involved in leukosogenesis in young and elderly AML patients.

About the authors

Sergey Vasil'evich Gritsaev

Email: rniiht@mail.ru

Irina Stepanovna Martynkevich

Email: genetics.spb@mail.ru

Lyudmila Sergeevna Martynenko

Email: genetics.spb@mail.ru

Marina Petrovna Ivanova

Email: genetics.spb@mail.ru

Vasilisa Yur'evna Aksenova

Email: genetics.spb@mail.ru <mailto:genetics.spb@mail.ru>

Mikhail Viktorovich Moskalenko

Email: genetics.spb@mail.ru <mailto:genetics.spb@mail.ru>

Irina Mikhaylovna Zapreeva

Email: rniiht@mail.ru

Kudrat Mugutdinovich Abdulkadyrov

Email: rniiht@mail.ru

S V Gritsaev

Russian Research Institute of Hematology and Transfusiology, St-Petersburg

Russian Research Institute of Hematology and Transfusiology, St-Petersburg

I S Martynkevich

Russian Research Institute of Hematology and Transfusiology, St-Petersburg

Russian Research Institute of Hematology and Transfusiology, St-Petersburg

L S Martynenko

Russian Research Institute of Hematology and Transfusiology, St-Petersburg

Russian Research Institute of Hematology and Transfusiology, St-Petersburg

M P Ivanova

Russian Research Institute of Hematology and Transfusiology, St-Petersburg

Russian Research Institute of Hematology and Transfusiology, St-Petersburg

V Yu Aksenova

Russian Research Institute of Hematology and Transfusiology, St-Petersburg

Russian Research Institute of Hematology and Transfusiology, St-Petersburg

M V Moskalenko

Russian Research Institute of Hematology and Transfusiology, St-Petersburg

Russian Research Institute of Hematology and Transfusiology, St-Petersburg

I M Zapreeva

Russian Research Institute of Hematology and Transfusiology, St-Petersburg

Russian Research Institute of Hematology and Transfusiology, St-Petersburg

K M Abdulkadyrov

Russian Research Institute of Hematology and Transfusiology, St-Petersburg

Russian Research Institute of Hematology and Transfusiology, St-Petersburg

Sof'ya Aleksandrovna Tiranova

Email: rniiht@mail.ru

References

  1. Pulte D., Gondos A., Brenner H. Improvements in survival of adults diagnosed with acute myeloblastic leukemia in the early 21-st century. Haematologica 2008; 93: 594-600.
  2. Derolf A. R., Kristinsson S. Y., Andersson T. M. L. et al. Improved patient survival for acute myeloid leukemia: a population-based study of 9729 patients diagnosed in Sweden between 1973 and 2005. Blood 2009; 113: 3666-3673.
  3. Deschler B., de Witte T., Mrtelsmann R., Lubbert M. Treatment decision-making for older patients with high-risk myelodysplastic syndrome or acute myeloid leukemia: problems and approaches. Haematologica 2006; 91: 1513-1522.
  4. Frohling S., Schlenk R. F., Kayser S. et al. Cytogenetics and age are the major determinant of outcome in intensively treated acute myeloid leukemia patients older than 60 years: results from the AMLSG trial AML HD98-B. Blood 2006; 108: 3280-3288.
  5. Goldstone A. H., Burnett A. K., Wheatley K. et al. Attempts to improve treatment outcomes in acute myeloid leukemia (AML) in older patients: the results of the United Kingdom Medical Research Council AML 11 trial. Blood 2001; 98: 1302-1311.
  6. Kantarjian H., O'Brien S., Cortes J. et al. Results of intensive chemotherapy in 998 patients age 65 years or older with acute myeloid leukemia or high-risk myelodysplastic syndrome: predictive prognostic models for outcome. Cancer 2006; 106: 1090-1098.
  7. Appelbaum F. R., Gundacker H., Head D. R. et al. Age and acute myeloid leukemia. Blood 2006; 107: 3481-3485.
  8. Bacher U., Kern W., Schnittger S. et al. Population-based age-specific incidences of cytogenetic subgroups of acute myeloid leukemia. Haematologica 2005; 90: 1502-1510.
  9. Moorman A. V., Roman E., Cartwright R. A., Morgan G. J. Age-specific incidence rates for cytogenetically-defined subtypes of acute myeloid leukemia. Br. J. Cancer 2002; 86: 1061-1063.
  10. Preiss B. S., Kerndrup G. B., Schmidt K. G. et al. Cytogenetic findings in adult de novo acute myeloid leukemia. A population-based study of 303/337 patients. Br. J. Haematol. 2003; 123: 219-234.
  11. Grimwade D., Hills R. K. Independent prognostic factors for AML outcome. Hematology (Am. Soc. Hematol. Educ. Program.). 2009. 385-395.
  12. Breems D. A., Van Putten W. L. J., De Greef G. E. et al. Monosomal karyotype in acute myeloid leukemia: a better indicator of poor prognosis than a complex karyotype. J. Clin. Oncol. 2008; 26: 4791-4797.
  13. Vardiman J. W., Thiele J., Arber D. A. et al. The 2008 revision of the World Health Organisation (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes. Blood 2008; 114: 937-951.
  14. Byrd J. C., Mryzek K., Dodge R. K. et al. Pretreatment cytogenetic abnormalities are predictive of induction success, cumulative incidence of relapse, and overall survival in adult patients with de novo acute myeloid leukemia: results from Cancer and Leukemia Group B (CALGB 8461). Blood 2002; 100: 4325-4336.
  15. Malfuson J. V., Etienne A., Turlure P. et al. Risk factors and decision criteria for intensive chemotherapy in older patients with acute myeloid leukemia. Haematologica 2008; 93: 1806- 1813.
  16. Farag S. S., Archer K. J., Mrozek K. et al. Pretreatment cytogenetics add to other prognostic factors predicting complete remission and long-term outcome in patients 60 years of age or older with acute myeloid leukemia: results from Cancer and Leukemia Group B 8461. Blood 2006; 108: 63-73.
  17. Gardin C., Turlure P., Fagot T. et al. Postremission treatment of elderly patients with acute myeloid leukemia in first complete remission after intensive induction chemotherapy: results of the multicenter randomized Acute Leukemia French Association (ALFA) 9803 trial. Blood 2007; 109: 5129-5135.
  18. Moorman A. V., Roman E., Willett E. V. et al. Karyotype and age in acute myeloid leukemia. Are they linked? Cancer Genet. Cytogenet. 2001; 126: 155-161.
  19. Grimwade D., Walker H., Oliver F. et al. The importance of diagnostic cytogenetics on outcome in AML: analysis of 1612 patients entered into the MRC AML 10 trial. The Medical Research Council Adult and Children's Leukemia Working Parties. Blood 1998; 92: 2322-2333.
  20. Rossi G., Pellizzari A. M., Bellotti D. et al. Cytogenetic analogy between myelodysplastic syndrome and acute myeloid leukemia. Leukemia 2000; 14: 636-641.
  21. Dohner K., Dohner H. Molecular characterization of acute myeloid leukemia. Haematologica 2008; 93: 976-982.
  22. Renneville A., Roumier C., Biggio V. et al. Cooperating gene mutations in acute myeloid leukemia: a review of the literature. Leukemia 2008; 22: 915-931.
  23. Mead A. J., Linch D. C., Hills R. K. et al. FLT3 tyrosyne kinase domain mutations are biologically distinct from and have a significantly more favorable prognosis than FLT3 internal tandem duplication in patients with acute myeloid leukemia. Blood 2007; 110: 1262-1270.
  24. Verhaak R. G., Goudswaard C. S., van Putten W. et al. Mutations in nucleophosmin in acute myeloid leukemia: association with other gene abnormalities and previously established gene expression signature and their favorable prognostic significance. Blood 2005; 106: 3747-3754.
  25. Bacher U., Haferlach T., Kern W. et al. A comparative study of molecular mutations in 381 patients with myelodysplastic syndrome and in 4130 patients with acute myeloid leukemia. Haematologica 2007; 92: 744-752.
  26. Lindvall C., Furge K., Bjorkholm M. et al. Combined genetic and transcriptional profiling of acute myeloid leukemia with normal and complex karyotypes. Haematologica 2004; 89: 1072-1081.
  27. Mills K. I., Kohlmann A., Williams P. M. et al. Microarray-based classifiers and prognosis models identify subgroups with distinct clinical outcomes and high risk of AML transformation of myelodysplastic syndrome. Blood 2009; 114: 1063- 1072.
  28. Fernandez H. F., Sun Z., Yao X. et al. Anthracycline dose intensification in acute myeloid leukemia. N. Engl. J. Med. 2009; 361: 1249-1259.
  29. Lowenberg B., Ossenkoppele G. J., van Putten W. et al. High-dose daunorubicin in older patients with acute myeloid leukemia. N. Engl. J. Med. 2009; 361: 1235-1248.

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

Copyright (c) 2011 Consilium Medicum

Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
 

Address of the Editorial Office:

  • Alabyan Street, 13/1, Moscow, 127055, Russian Federation

Correspondence address:

  • Alabyan Street, 13/1, Moscow, 127055, Russian Federation

Managing Editor:

  • Tel.: +7 (926) 905-41-26
  • E-mail: e.gorbacheva@ter-arkhiv.ru

 

 © 2018-2021 "Consilium Medicum" Publishing house


This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies